In this study, the authors explored the pharmacokinetics and safety of bictegravir in pregnancy and the postpartum period among maternal-infant pairs.
Citation: Powis, K.M., Pinilla, M., McMorrow, F., Stek, A., Brooks, K.M., Shapiro, D.E., Knowles, K., Eke, A.C., Greene, E., Agwu, A., Topete, L., Browning, R., Chakhtoura, N., Arora, P., Huang, X., Best, B.M., Mirochnick, M., Momper, J.D., IMPAACT 2026 Protocol Team. Pharmacokinetics and safety of bictegravir in pregnant and postpartum persons With HIV and their infants. J Acquir Immune Defic Syndr. 2025 Mar 1;98(3):300-307.
Article (subscription may be required)